Cell-penetrating peptides have revolutionized intracellular drug delivery by solving the membrane permeability barrier.
Discovery and History
TAT Peptide (1988) - HIV-1 Trans-Activator of Transcription - Found to enter cells and nucleus - First CPP characterized - Sequence: GRKKRRQRRRPPQ
Penetratin (1994) - From Antennapedia homeodomain (Drosophila) - Sequence: RQIKIWFQNRRMKWKK - Established CPP field
Classification of CPPs
By Charge
- Rich in Arg and Lys
- Examples: TAT, R8, R9 (polyarginine)
- Interact with membrane proteoglycans
- Most common class
- Hydrophobic + charged regions
- Examples: Penetratin, Transportan
- Can partition into membranes
- Primarily nonpolar
- Examples: Signal peptide-derived
- Less common, require modification
By Origin
| Source | Example | Length |
|---|---|---|
| Viral protein | TAT | 13 AA |
| Homeodomain | Penetratin | 16 AA |
| Chimeric | Transportan | 27 AA |
| Synthetic | Polyarginine | Variable |
| Antimicrobial | Buforin II | 21 AA |
Mechanisms of Entry
Direct Translocation - CPP directly crosses membrane - Transient pore formation - Energy-independent - Occurs at high concentrations
Endocytosis - CPP internalized via vesicles - Energy-dependent - Multiple pathways: - Macropinocytosis (most common) - Clathrin-mediated - Caveolin-mediated
The Arginine Paradox Why polyarginine works: - Arginine guanidinium group - Forms bidentate hydrogen bonds - Interacts with phosphate headgroups - Creates transient membrane defects
Cargo Delivery
What CPPs Can Deliver
| Cargo | Size | Strategy |
|---|---|---|
| Small molecules | <1 kDa | Covalent conjugation |
| Peptides | 1-5 kDa | Fusion or conjugation |
| Proteins | 10-100 kDa | Covalent or non-covalent |
| Nucleic acids | Variable | Electrostatic complex |
| Nanoparticles | 10-200 nm | Surface modification |
Attachment Strategies
- Disulfide bonds (cleavable)
- Maleimide chemistry
- Click chemistry
- Genetic fusion
- Electrostatic complexation (nucleic acids)
- Hydrophobic interaction
- Streptavidin-biotin
Challenges and Solutions
Endosomal Escape **Problem:** Most cargo trapped in endosomes **Solutions:** - Histidine-rich sequences (buffer) - Membrane-lytic peptides - Photochemical internalization - pH-responsive design
Cell Type Selectivity **Problem:** CPPs enter all cells **Solutions:** - Targeting ligands - Activatable CPPs - Cell-specific proteases
Toxicity **Problem:** Membrane disruption at high doses **Solutions:** - Lower concentrations - Transient exposure - Design optimization
Clinical Development
Current Status - Several CPP-drug conjugates in trials - No FDA-approved CPP drugs yet - Active area of research
Examples in Development
- Eteplirsen (Exondys 51) uses cell-penetrating morpholino
- Approved for Duchenne muscular dystrophy
- p28 (tumor suppressor peptide)
- Phase 1 for cancer